Outcomes of Active Surveillance for Clinically Localized Prostate Cancer in the Prospective, Multi-Institutional Canary PASS Cohort

Journal of Urology

Volumn 195, Issue 2, 2016, Pages 313-320

  Newcomb, Lisa F ^a,b   Thompson, Ian M ^g   Boyer, Hilary D ^a   Brooks, James D ^d   Carroll, Peter R ^e   Cooperberg, Matthew R ^e   Dash, Atreya ^c   Ellis, William J ^b   Fazli, Ladan ^f   Feng, Ziding ^a   Gleave, Martin E ^f   Kunju, Priya ^k   Lance, Raymond S ⁱ   McKenney, Jesse K ^j   Meng, Maxwell V ^e   Nicolas, Marlo M ^g   Sanda, Martin G ^h   Simko, Jeffry ^e   So, Alan ^f   Tretiakova, Maria S ^b   Troyer, Dean A ⁱ   True, Lawrence D ^b   Vakar Lopez, Funda ^b   Virgin, Jeff ^c   Wagner, Andrew A ^h   Wei, John T ^k   Zheng, Yingye ^a   Nelson, Peter S ^a   Lin, Daniel W ^a,b,c   more..

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d STANFORD UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

ⁱ EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^j LERNER RESEARCH INSTITUTE   (United States)

^k UNIVERSITY OF MICHIGAN   (United States)

more..

Author keywords

prospective studies; prostatic neoplasms; watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BODY MASS; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SIZE; CANCER SURGERY; COHORT ANALYSIS; FOLLOW UP; GLEASON SCORE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TREATMENT DURATION; BIOPSY; CANCER GRADING; CLINICAL TRIAL; HEALTH SURVEY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROSTATIC NEOPLASMS; RISK FACTOR; TREATMENT OUTCOME; TUMOR VOLUME; WATCHFUL WAITING;

AGED; BIOMARKERS, TUMOR; BIOPSY; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; WATCHFUL WAITING;

EID: 84953768677     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2015.08.087     Document Type: Article

References (27)

1. P.C. Albertsen, J.A. Hanley, and J. Fine 20-Year outcomes following conservative management of clinically localized prostate cancer JAMA 293 2005 2095
2. M.R. Cooperberg, J.M. Broering, and P.R. Carroll Time trends and local variation in primary treatment of localized prostate cancer J Clin Oncol 28 2010 1117
3. R. Etzioni, D.F. Penson, J.M. Legler, and et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends J Natl Cancer Inst 94 2002 981
4. M.R. Cooperberg, J.M. Broering, P.W. Kantoff, and et al. Contemporary trends in low risk prostate cancer: risk assessment and treatment J Urol 178 suppl. 2007 S14
5. D.C. Miller, S.B. Gruber, B.K. Hollenbeck, and et al. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States J Natl Cancer Inst 98 2006 1134
6. L.F. Newcomb, J.D. Brooks, P.R. Carroll, and et al. Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository Urology 75 2010 407
7. J.I. Epstein, W.C. Allsbrook Jr., M.B. Amin, and et al. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma Am J Surg Pathol 29 2005 1228
8. J.L. Mohler, P.W. Kantoff, A.J. Armstrong, and et al. Prostate cancer, version 1.2014 J Natl Compr Canc Netw 11 2013 1471
9. V.A. Moyer U.S. Preventive Services Task Force Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 157 2012 120
10. M.A. Dall'Era, B.R. Konety, J.E. Cowan, and et al. Active surveillance for the management of prostate cancer in a contemporary cohort Cancer 112 2008 2664
11. L. Klotz, D. Vesprini, P. Sethukavalan, and et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer J Clin Oncol 33 2015 272
12. J.J. Tosoian, B.J. Trock, P. Landis, and et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience J Clin Oncol 29 2011 2185
13. M. Bul, X. Zhu, R. Valdagni, and et al. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study Eur Urol 63 2013 597
14. M.R. Cooperberg, S.J. Freedland, D.J. Pasta, and et al. Multiinstitutional validation of the UCSF Cancer of the Prostate Risk Assessment for prediction of recurrence after radical prostatectomy Cancer 107 2006 2384
15. D.F. Gleason, and G.T. Mellinger Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging J Urol 111 1974 58
16. M.W. Kattan, J.A. Eastham, A.M. Stapleton, and et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer J Natl Cancer Inst 90 1998 766
17. S.J. Freedland, W.J. Aronson, M.K. Terris, and et al. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database J Urol 169 2003 2136
18. T. Tsuzuki, D.J. Hernandez, H. Aydin, and et al. Prediction of extraprostatic extension in the neurovascular bundle based on prostate needle biopsy pathology, serum prostate specific antigen and digital rectal examination J Urol 173 2005 450
19. M.R. Cooperberg, D.J. Pasta, E.P. Elkin, and et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy J Urol 173 2005 1938
20. M.A. Dall'Era, P.C. Albertsen, C. Bangma, and et al. Active surveillance for prostate cancer: a systematic review of the literature Eur Urol 62 2012 976
21. C. Warlick, B.J. Trock, P. Landis, and et al. Delayed versus immediate surgical intervention and prostate cancer outcome J Natl Cancer Inst 98 2006 355
22. M. Truong, J.A. Slezak, C.P. Lin, and et al. Development and multi-institutional validation of an upgrading risk tool for Gleason 6 prostate cancer Cancer 119 2013 3992
23. J.I. Epstein Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens J Urol 186 2011 790
24. B. Bhindi, G.S. Kulkarni, A. Finelli, and et al. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly Eur Urol 66 2014 841
25. J.K. McKenney, J. Simko, M. Bonham, and et al. The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study J Urol 186 2011 465
26. D.W. Lin, L.F. Newcomb, E.C. Brown, and et al. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study Clin Cancer Res 19 2013 2442
27. T.J. Wilt, M.K. Brawer, K.M. Jones, and et al. Radical prostatectomy versus observation for localized prostate cancer N Engl J Med 367 2012 203